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Summary To determine the clinical significance of MRP in patients with colorectal carcinomas, we have studied the expression of the MRP
gene by reverse transcription-polymerase chain reaction (RT-PCR) (n=105) and by immunohistochemistry (n=30). MRP mRNA expression
was observed in 92 (88%) tumour specimens. Positive MRP staining with monoclonal antibodies QCRL-1 and QCRL-3 was detected in all
samples studied with strong staining in seven (23%) and weak staining in 23 (77%) specimens. Strong MRP staining in these samples did not
appear to be related to the age and sex of the patients, localization of the primary tumour, histological grade, tumour size, lymph node
metastasis, distant metastasis and tumour stage. Strong MRP staining was not associated with MDR1 RNA or P-glycoprotein (P-gp)
expression. Kaplan-Meier curves revealed that overall survival of patients with strong MRP-staining tumours was similar to the survival of
patients with weak-staining tumours. These data indicate that the MRP gene is expressed in primary colorectal carcinomas but is neither
related to known prognostic factors nor a prognostic factor by itself.
Keywords: colorectal carcinoma; multidrug resistance; MRPgene; multidrug resistance-associated protein
Drug resistance remains a major problem in patients with
colorectal carcinomas, which are usually intrinsically resistant to
anti-cancer drugs. The clinically relevant mechanisms of drug
resistance arecurrently underinvestigation. One important mecha-
nism may be the multidrug-resistance phenotype (Pastan and
Gottesman, 1987; Gottesman and Pastan, 1988; Simon and
Schindler, 1994). Multidrug resistance (MDR) is the term for the
resistance against a variety of hydrophobic natural compounds,
including several anti-cancer drugs (Pastan and Gottesman, 1987).
MDR is caused in part by overexpression of the MDRJ gene
(Goldstein et al, 1989). This gene codes forP-glycoprotein (P-gp),
a 170-kDa transmembrane protein, which may function as an
energy-dependent drug efflux pump (Pastan and Gottesman, 1987;
Gottesman and Pastan, 1988). Besides the 'active drug pump
model', the 'altered partitioning model' is discussed. The latter
model proposes that altered sequestration ofanti-cancer drugs and
other compounds is the indirect result ofperturbations in the char-
acter and/or magnitude of eukaryotic plasma membrane electro-
chemical potential caused by P-gp overexpression (Roepe, 1995).
Expression of MDR] mRNA and P-gp was demonstrated in 65%
and 68% ofprimary colorectal carcinomas respectively (Weinstein
et al, 1991; Pirker et al, 1993). Although MDR was previously
thought to be predominantly caused by the expression of the
MDRJ gene, it is now increasingly believed to be caused by other
mechanisms also (Roepe et al, 1993; Simon and Schindler, 1994;
Filipits et al, 1996a).
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Recently, overexpression ofthe multidrug resistance-associated
protein (MRP) was suggested as a possible mechanism for non-
P-gp-mediated MDR (Cole et al, 1992; Barrand et al, 1994). This
190-kDa membrane protein is encoded by the MRP gene, which
has recently been cloned (Cole et al, 1992). Transfection studies
have demonstrated that overexpression of human MRP confers
a multidrug-resistance phenotype (Grant et al, 1994; Kruh et al,
1994; Zaman et al, 1994). MRP is believed to be involved in the
ATP-dependent transport ofcysteinyl leukotrienes (e.g. LTC4) and
other glutathione-S-conjugates (Loe et al, 1996). MRP has also
been suggested to be involved in the transport ofvincristine in the
presence of reduced glutathione (Loe et al, 1996). However, the
exact mechanisms by which MRP mediates resistance to anti-
cancer drugs remains to be determined.
The aim of our present study was, firstly, to determine the
expression of the MRP gene in primary colorectal carcinomas in
order to evaluate the clinically active mechanisms of MDR in
these tumours further, and, secondly, to assess its association with
other clinical parameters, including the survival ofpatients.
PATIENTS AND METHODS
Patients
Between 1988 and 1995, 105 patients with colorectal carcinomas
were admitted to this study. Sixty-five patients had been included
in aprevious study (Pirkeret al, 1993). The patients were treated at
the Surgical Department of the General Hospital of Wiener
Neustadt, Austria.
Forty-two patients received adjuvant chemotherapy with 5-
fluorouracil and leucovorin as described (Pirker et al, 1993).
During metastatic disease, patients were usually treated with 5-
fluorouracil with or without leucovorin and occasionally also with
cisplatin and drugs to which P-gp overexpression may confer
resistance (mitoxantrone and mitomycin C).
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Tumour specimens and cell lines
Colorectal carcinoma specimens and adjacent normal tissue speci-
mens were obtained by surgery and stored at -80°C until use.
Samples were graded for histological type and Dukes' stage
according to standard criteria. Peripheral blood mononuclear cells
were obtained from healthy volunteers by Ficoll-Paque gradient
centrifugation. KB-3-1 and KB-8-5 cells (provided by Drs I Pastan
and M Gottesman, National Cancer Institute, Bethesda, MD,
USA) were grown as described (Pirker et al, 1991). Cytospins of
Cl and T5 cells as well as cDNAs synthesized from RNA that had
been isolated from these cells were kindly provided by Drs S Cole
and R Deeley (Queen's University, Kingston, Canada).
Analysis of gene expression by RT-PCR
Total RNA was extracted from tumour specimens by means of
RNAzol (Cinna Scientific, Cincinnati, OH, USA) and quantitated
spectrophotometrically. MRP RNA was determined as described
recently (Filipits et al, 1996b).
Briefly, 5-10 gg of total RNA was used for cDNA synthesis
using Moloney murine leukaemia virus reverse transcriptase
(Promega) in a total volume of 50gl. After 1 h incubation at
37°C, 5 min at 95°C and a quick chill to 4°C, cDNA was stored
at -20°C until use.
The cDNA reaction mixture (5-10 tl) was used for amplifica-
tion of specific DNA sequences. A total of 30-35 cycles at
95°C for 25 s, 57°C for 30 s and 73°C for 1 min and a quick chill
to 4'C in a 9600 thermocycler (Perkin Elmer Cetus, Emeryville,
CA, USA) were performed. Samples, which were MRP mRNA
negative after 30 cycles, were re-evaluated with 35 cycles under
otherwise unchanged conditions. In this study, all oligonucleotides
used as primers were synthesized by Fa. Biomedica (Vienna,
Austria). The primers were chosen as follows: 5'-TGAAG-
GACTTCGTGTCAGCC-3' (forward primer; residues
4419-4438) and 5'-GTCCATGATGGTGTTGAGCC-3' (reverse
primer; residues 4656-4675) of the MRP gene (Zaman et al,
1993), 5'-ACCCCCACTGAAAAAGATGA-3' (forward primer;
residues 1544-1563) and5'-ATCTTCAAACCTCCATGATG-3'
( r e v e r s e p r i m e r
residues 2253-2262 and 3508-3517) of the f32-microglobulin
(J32-m) gene (Noonan et al, 1990), and 5'-CCCATCATTG-
CAATAGCAGG-3' (forward primer; residues 2596-2615) and 5'-
GTTCAAACTTCTGCTCCTGA-3' (reverse primer; residues
2733-2752) of the MDR] gene (Noonan et al, 1990). All corre-
sponding pairs ofthe primers spanned an intron to control against
contamination by amplification of genomic DNA sequences. The
sizes of the PCR products are 256 bp (MRP), 120 bp (02-m) and
167 bp(MDRJ) respectively. Expression of132-m RNA was used as
an internal control for bothMDRJ and MRP gene expression.
Immunohistochemical analysis
Monoclonal antibodies QCRL-1 and QCRL-3 (kindly provided by
Drs S Cole and R Deeley, Queen's University, Kingston, Canada),
which recognize different epitopes of MRP (Hipfner et al, 1994),
as well as monoclonal antibodies C219 and MRK16, which recog-
nize different epitopes of P-gp, were used for immunohisto-
chemistry as described previously (Filipits et al, 1996b).
Cryostat sections (4 jum) ofthe colorectal carcinoma specimens
were prepared. Serial sections were used for MRP and P-gp
Table 1 MRPand MDR1 gene expression in colorectal carcinoma specimens
(a) RT-PCR
Negative (%) Positive (%)
MRP RNA (n-=105) 13 (12) 92 (88)
MDR1 RNA (rn100) 17 (17) 83 (83)
(b) Immunohistochemistry
Negative (5) Weak (%) Strong (%)
MRP (n=30) 0 ( 0) 23 (77) 7 (23)
P-gp
C219 (n=30) 18 (60) 8 (27) 4 (13)
MRK16 (n=30) 16 (53) 9 (30) 5 (17)
staining. The slides were air dried overnight and fixed in cold
acetone (QCRL-1, QCRL-3 and C219) or paraformaldehyde
(MRK16). After blocking of endogenous peroxidase activity, the
slides were incubated with normal goat serum followed by 2 h
incubation with the primary antibodies. Antibody binding was
detected by the avidin-biotin-peroxidase method. Negative
controls were performed without the primary antibodies for each
sample and, in addition, with irrelevant isotype-matched anti-
bodies in some cases. Cl and T5 cells were used as negative and
positive controls for MRP expression (Grant et al, 1994). Drug-
sensitive KB-3-1 and multidrug-resistant KB-8-5 cells served as
negative and positive controls for P-gp expression respectively.
Immunostained slides were independently examined by two
observers who had no previous knowledge ofthe clinical outcome
ofthe patients. MRP and P-gp immunostaining were evaluated and
scored separately.
Survival analysis
Durations of overall survival (OS) were estimated according to
Kaplan and Meier (1958). OS was measured from the time ofdiag-
nosis until the time of death or in the case of censored patients
until the time ofthe last control.
Statistical analysis
Frequencies were examined by chi-square tests. In addition,
Kruskal-Wallis tests were performed. Survival curves were
compared by the Wilcoxon test.
RESULTS
MRP expression in colorectal carcinoma specimens
MRP mRNA expression of primary colorectal carcinoma speci-
mens (n=105) was determined by RT-PCR. Drug-sensitiveCl and
drug-resistant T5 cells were used as negative and positive controls
respectively. In addition, peripheral blood mononuclear cells
served as positive controls. TheP2-m gene, which was coamplified
with the MRP gene, was used as an internal control. Ninety-two
(88%) colorectal carcinomas did express MRP mRNA (Table 1).
Thirteen carcinomas were negative for MRP mRNA (Table 1) and
remained negative when the number ofRT-PCR cycles was raised
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Table 2 MRP and clinical parameters of the patients
All patients Patients with weak Patients with strong P-value
MRP staining MRP staining
Number of patients 30 23 ( 77) 7 (23)
Age (years)
Median 65 66 60 NS
Range 49-81 49-81 4N73
Sex (F/M) 10/20 8/15 2/5 NS
Localization
Colon 16 12 ( 75) 4 (25) NS
Rectum 14 11 ( 79) 3 (21)
Histological grade
GO-1 6 3(50) 3 (50) NS
G2-3 24 20( 83) 4(17)
Primary tumour
T1-2 7 5( 71) 2 (29) NS
T3-4 23 18( 78) 5 (22)
Regional lymph nodes
NO 13 9 (69) 4 (31)
Ni 12 10( 83) 2(17) NS
N2 3 2 (67) 1 (33)
N3 2 2(100) 0( 0)
Distant metastasis
MO 28 21 ( 75) 7 (25) NS
Ml 2 2(100) 0( 0)
Tumour stage (Dukes' stage)
A2 3 2 (67) 1 (33)
B 10 7 (70) 3 (30)
Cl 10 9(90) 1 (10) NS
C2 5 3(60) 2 (40)
D 2 2 (100) 0 ( 0)
MDR1
MDR1 RNA positive 24 19 ( 79) 5 (21)
P-gp (C219) positive 12 9 ( 75) 3 (25) NS
P-gp (MRK16) positive 14 9 ( 64) 5 (36)
Treated with chemotherapy 18 15 ( 83) 3 (17) NS
Treated with MDR drugs 7 5 ( 71) 2 (29) NS
MRP expression of colorectal carcinoma specimens was determined by immunohistochemistry and
correlated with clinical parameters of the patients. Statistical analysis was performed by either
Kruskal-Wallis or chi-square test. Numbers in parentheses are percentages. NS, not significant.
from 30 to 35 (data not shown).
Immunohistochemistry
MRP expression at the protein level was immunohistochemically
determined by means of monoclonal antibodies, QCRL-1 and
QCRL-3, on frozen sections ofcolorectal carcinomas and, in some
cases, also on adjacent normal tissue specimens. Non-specific
binding was excluded by controls either with irrelevant isotype-
matched monoclonal antibodies (IgG, and IgG2A) or without
primary antibodies.
Immunohistochemical analysis was performed in 30 out of the
105 colorectal carcinoma specimens studied by RT-PCR. All ofthe
30 specimens showed detectable levels ofMRP RNA. Both plasma
membrane and cytoplasmatic MRP staining patterns were seen.
With regard to the degree ofMRP expression, patients were divided
according to the intensity of staining into a group with strong and a
second group with only weak staining. Staining of the positive
control cell line T5 was chosen as very strong and above the inten-
sity seen in clinical samples. Staining with anti-MRP antibodies was
strong in seven (23%) specimens andonly weak in theremaining 23
(77%) samples (Table 1). In the case ofstrong staining, the majority
of tumour cells within the specimens were affected. Completely
negative MRP staining was not seen in any ofthe carcinoma speci-
mens. Unfortunately, no samples from RT-PCR-negative tumours
were available for immunohistochemistry.
In addition, MRP expression of normal colon tissue adjacent to
the carcinomas was assessed in some samples. Whereas MRP
staining could be detected in all normal colon tissues, strong MRP
staining occurred predominantly on the luminal surface of crypt
epithelial cells.
Relationship between the MRPgene and the MDR1 gene
In order to assess the relationship between the MRP and theMDRJ
gene, we compared the expression ofboth genes. MDRJ RNA was
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Figure 1 MRP expression and overall survival. Overa
patients with weak (n=23) or strong MRP staining (n=
according to Kaplan and Meier (1958). Statistical com
curves was done by the Wilcoxon test
determined by RT-PCR and was detected ir
(Table 1). P-gp expression was also studied
cally by means of the monoclonal antibodies
respectively, and was found to be positive i
staining) and 47% (17% strong staining) of th
respectively (Table 1). No significant correl
and MDRJ mRNA or P-gp expression was ob
MRP in relation to clinical parameters
Next, we evaluated the association of MRP g
clinical parameters. Histological examinatior
cinomas in all cases (data not shown). MRP gc
tumours did not appear to be related to sex an4
localization and size of the primary tumour
tumour infiltration of the lymph nodes, dis
tumour stage (Table 2).
To evaluate whether strong MRP staining
prognostic value, Kaplan-Meier analysis of
performed in 30 patients. At a median follo
overall survival ofpatients with weak-staining
to the survival ofpatients with strong-staining
DISCUSSION
In the present study, expression ofMRP RNA
of the primary colorectal carcinomas. MRI
immunohistochemistry, was expressed in all
with strong staining in 23% ofthe samples. TI
that the MRP gene might contribute to the intr
of colorectal carcinomas. Previously, expre
gene, which was seen in approximately two
colorectal carcinomas, was thought to be the
nism ofMDR in these tumours (Goldstein et a
al, 1991; Pirker et al, 1993; Sinicrope et al, 1'
of strong MRP-staining tumours is consist
report on MRP expression in four out of 12 (3.
nomas (Nooter et al, 1995). The percenta
tumours in our study (40% and 47%) is also si
ages previously reported (Weinstein et al, 199
De Angelis et al, 1995).
Strong MRP staining did not appear to be related to size of the
primary tumour, lymph node involvement, distant metastasis,
tumour stage and survival of the patients (Table 2). Thus, MRP
was not related to established prognostic factors and was not of
Strong prognostic value by itself. Lack of an association of MRP gene
expression and clinical outcome of the patients can be explained
Weak by several reasons. Firstly, the clinical behaviour of the tumours is
independent of MRP expression. In lung tumours, MRP RNA
p= 0.5 expression was suggested to be involved in invasion because it
was more prominent in cells at the leading edge of the tumours,
but no data on its relation to the survival of the patients are
50 60 70 reported (Thomas et al, 1994). Secondly, a functionally active
MRP gene was most likely without clinical impact because most
patients were not treated with MDR drugs and because the activity
7) was calculated of 5-fluorouracil is not affected by MRP. Finally, a type II statis-
iparison between the tical error cannot be excluded. Therefore, it might be worthwile to
confirm these results in a larger study population.
In one report, P-gp expression was observed predominantly in
invasively growing tumour cells, suggesting that P-gp expression
is associated with local tumour aggressiveness (Weinstein et al,
n 83 (83%) samples 1991). Despite these findings however, neither MDRJ mRNA nor
immunohistochemi- P-gp expression ofthe tumours was of prognostic value in patients
s C219 and MRK16 with colorectal carcinomas (Mayer et al, 1993; Pirker et al, 1993).
in 40% (13% strong No correlation between MRP gene expression and MDRJ gene
ie tumour specimens expression was observed (Table 2). In contrast to these results,
ation between MRP sequential coexpression of the MRP and the MDR] gene was
iserved (Table 2). detected in etoposide-selected H69 small-cell lung cancer cells
(Brock et al, 1995).
Recently, one mutant p53 has been shown to stimulate the
MDRJ promoter in vitro, whereas wild-type p53 represses its
;ene expression with activity (Chin et al, 1992). In colorectal carcinoma specimens,
l revealed adenocar- however, P-gp expression was independent of p53 expression or
ene expression ofthe the incidence of p53 mutations (De Angelis et al, 1995),
d age ofthe patients, suggesting that mutant p53 does not induce overexpression of
histological grade, P-gp in colorectal carcinomas. MRP gene expression correlated
stant metastasis and with amplification and overexpression of the n-myc oncogene
in childhood neuroblastoma (Bordow et al, 1994; Norris et al,
of the tumours is of 1996). Thus, future studies will have to define further the relation-
overall survival was ship between drug resistance genes and oncogenes or tumour-
ow-up of 39 months, suppressor genes in colorectal carcinomas.
tumours was similar MRP gene expression could be involved in the clinically well-
tumours (Figure 1). known intrinsic resistance of colorectal carcinomas to MDR
drugs. Because in vitro MRP is believed to be involved in the
transport of certain anti-cancer drugs, including anthracyclines
and vinca alkaloids (Cole et al, 1994; Grant et al, 1994), it is antic-
was detected in 88% ipated that this function also contributes to the inactivity of these
P, as determined by drugs in the treatment of colorectal carcinomas. Expression of
tumour specimens, MRP might also be one of the reasons why previous clinical trials
hese findings suggest with resistance modifiers of the MDRJ gene (Pirker et al, 1990;
rinsic drug resistance Twentyman, 1992) failed in patients with colorectal carcinomas
ssion of the MDR] and other tumours (Lehnert, 1993; Milroy et al, 1993).
out of three primary In conclusion, multidrug resistance in colorectal carcinomas is a
predominant mecha- complex phenomenon probably involving both the MRP gene and
.1, 1989; Weinstein et the MDR] gene. Future studies will have to address their regula-
)94). Our percentage tion of expression and quantitative contribution to resistance to
tent with the recent anti-cancer drugs. The presence of MRP gene expression will
3%) colorectal carci- also have to be considered in the planning of future clinical trials
ge of P-gp-positive with drug resistance modifiers. In addition, other mechanisms
imilar to the percent- involved in the MDR of cell lines will also have to be studied in
1; Mayer et al, 1993; colorectal carcinomas (Beck, 1989; Simon and Schindler, 1994).
Only knowledge of all clinically important mechanisms of drug
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resistance might eventually enable clinicians to design ways to
overcome drug resistance and, thereby, improve the outcome of
chemotherapy in patients with colorectal carcinomas.
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